Mandate

Vinge advises Zengun Group AB

July 04, 2019 M&A

Vinge has advised Zengun Group AB (publ) in connection with the acquisition of the Zengun Group and in conjunction with a bond issue.

Vinge has advised Zengun Group AB (publ), in connection with the acquisition of the Zengun Group and in conjunction with a bond issue. The construction group Zengun’s founders have, together with the other owners and senior officers, through Zengun Group AB (publ) (the “Company”) repurchased the shares in Zengun Group Holding AB from Segulah Fund V.

In connection with the acquisition, the Company has issued a secured bond in an amount of MSEK 450. The bond, with an interest amount of MSEK 600, is subject to a variable interest rate of STIBOR 3m + 8 per cent and has a final due date in May 2022. The Company has prepared a prospectus which has been approved by and registered at the Swedish Financial Supervisory Authority in accordance with the Swedish Trading in Financial Instruments Act (1991:980) and will apply for listing of the bond on Nasdaq Stockholm.

Vinge’s team primarily consisted of Magnus Pauli, Frida Bergqvist, Lina André, Gabriella Varga, Camilla Andersson, Anna Åhlberg, Josefine Lanker and Jolinn Uhlin.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025